Business
Hemostemix Confirms OTCQB Listing
Calgary, Alberta--(Newsfile Corp. - October 28, 2021) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HM...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Confirms OTCQB ListingCalgary, Alberta--(Newsfile Corp. - October 28, 2021) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (\"Hemostemix\" or the \"Company\") is pleased to announce it is now up-listed to trade on the OTCQB under symbol HMTXF. The common shares of Hemostemix will continue to trade on the Frankfurt Stock Exchange under the symbol \"2VFO\" and trade on the TSX Venture Exchange under the symbol \"HEM\".ABOUT OTCQBThe OTCQB is recognized by the SEC as an established public market. As a verified market with efficient access to broker-dealers, Funds and U.S. investors, the OTCQB provides investors with transparent pricing and real-time quotes, convenient trading through a preferred broker, and trusted disclosure within an exchange-comparable information experience. The financial portals and online brokerages that display the OTCQB market designations include CNBC.com, Money.CNN.com, ETRADE.com, FT.com, OTCMarkets.com, Schwab.com, Scottrade.com, SeekingAlpha.com, Sharebuilder.com, SNL.com, TDAmeritrade.com, Tradeking.com, and TMX.com. Blue Sky compliant, OTCQB companies may subscribe to the OTCQB Blue Sky Monitoring Services to monitor their status in real-time, to increase liquidity and expand investment advisors' ability to research and recommend the security.The OTCQB offers introductions to best-in-class equity research, compliance, investor relations and communications services. HEMOSTEMIXHemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled \"Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up\" which noted healing of ulcers and resolut...